Locations:
Search
New guidelines from Brain Trauma Foundation urge early and aggressive treatment
Observational evidence of neuroprotection with GLP-1 receptor agonists and SGLT-2 inhibitors
Novel approach dramatically reduces the need for real-world data
Initial results show good accuracy of scalable, low-cost tool for flagging cognitive decline
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Genomic study lays groundwork for insights into potential biomarkers and therapeutic strategies
Large analysis of familial cases and genomic studies sheds light on genetic contributions
Proteins related to altered immune response are potential biomarkers of the rare AD variant
Alzheimer’s studies delve into sex-related variances in the expression of the disease
Early assessment could affect clinical decision making
Research combining genomics, database analysis and RNA sequencing suggests possible role for antiviral drug therapy
Advertisement
Advertisement